Mira Pharmaceuticals Secures Global Rights for MIRA-55 and SKNY-1 Drug Programs
MIRA sits 16% above its 52-week low of $0.9.
Summary
Mira Pharmaceuticals has secured amended exclusive worldwide rights for its MIRA-55 and SKNY-1 drug programs from Miralogx, enabling global development and commercialization. This follows an 8-K filed today and builds on recent positive preclinical data for both MIRA-55 and SKNY-1. The move strengthens the company's pipeline and intellectual property, which is crucial for a company operating under a 'going concern' warning. This provides a clearer path for potential future revenue from these assets.
At the time of this announcement, MIRA was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.4M. The 52-week trading range was $0.90 to $2.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.